U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H29N3O3
Molecular Weight 443.5375
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NNC-63-0532

SMILES

COC(=O)CN1CN(C2=CC=CC=C2)C3(CCN(CC4=C5C=CC=CC5=CC=C4)CC3)C1=O

InChI

InChIKey=AQMPIDSGLFVVPL-UHFFFAOYSA-N
InChI=1S/C27H29N3O3/c1-33-25(31)19-29-20-30(23-11-3-2-4-12-23)27(26(29)32)14-16-28(17-15-27)18-22-10-7-9-21-8-5-6-13-24(21)22/h2-13H,14-20H2,1H3

HIDE SMILES / InChI

Molecular Formula C27H29N3O3
Molecular Weight 443.5375
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

NNC 63-0532 is a potent non-peptide agonist for the KOR-3 (NOP receptor) (EC50 = 305 nM, Ki = 7.3 nM); about a 12-fold increase in selectivity over other receptors. NNC 63-0532 is an nociceptoid drug used in scientific research.

CNS Activity

Curator's Comment: Initial behavioural studies have shown that NNC 63-0532 induces e€ects that are consistent with central ORL1 activation upon peripheral (s.c.) administration (facilitation of lordosis behaviour and depression of locomotor activity), indicating that the compound does cross the blood brain barrier.

Originator

Curator's Comment: Novo Nordisk A/S, Department of Molecular Pharmacology, Novo Nordisk Park, Denmark.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
305.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
2004 Jun
Patents

Sample Use Guides

Rats: NNC 63-0532 was microinjected at 2, 20, and 200 nmol. The blockade of GABAA receptors in the dlSC elicited defensive alertness (Tukey’s post hoc test; p < 0.001) that was increased by the SNpr pretreatment with NNC 63-0532 at the highest dose (200 nmol)
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: A series of nociceptin receptor ligands has been investigated in relationship to their capability to promote receptor endocytosis, desensitization (evaluated as inhibition of forskolin-stimulated cAMP production) and compensatory upregulation of adenylyl cyclase activity in CHO-K1 cells expressing the cloned human nociceptin receptor.
Nociceptin (NC), [Arg14, Lys15]NC-NH2 and NNC 63-0532 (0.01 nM-10 uM) induce a concentration-dependent endocytosis and recycling of the nociceptin receptor.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:30:10 GMT 2023
Edited
by admin
on Sat Dec 16 09:30:10 GMT 2023
Record UNII
73663SY1DT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NNC-63-0532
Common Name English
1,3,8-TRIAZASPIRO(4.5)DECANE-3-ACETIC ACID, 8-(1-NAPHTHALENYLMETHYL)-4-OXO-1-PHENYL-, METHYL ESTER
Systematic Name English
Code System Code Type Description
PUBCHEM
9803475
Created by admin on Sat Dec 16 09:30:10 GMT 2023 , Edited by admin on Sat Dec 16 09:30:10 GMT 2023
PRIMARY
WIKIPEDIA
NNC 63-0532
Created by admin on Sat Dec 16 09:30:10 GMT 2023 , Edited by admin on Sat Dec 16 09:30:10 GMT 2023
PRIMARY
CAS
250685-44-0
Created by admin on Sat Dec 16 09:30:10 GMT 2023 , Edited by admin on Sat Dec 16 09:30:10 GMT 2023
PRIMARY
FDA UNII
73663SY1DT
Created by admin on Sat Dec 16 09:30:10 GMT 2023 , Edited by admin on Sat Dec 16 09:30:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID40397885
Created by admin on Sat Dec 16 09:30:10 GMT 2023 , Edited by admin on Sat Dec 16 09:30:10 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY